NextCure Files S-4 for Reverse Merger with Avere Therapeutics: Legacy Holders to Own ~1.17%
NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.1× avg).
Summary
NextCure filed its S-4 for the reverse merger with Avere Therapeutics, confirming legacy stockholders will own only ~1.17% of the combined company. The deal includes an $820M pre-closing financing and a proposed reverse stock split.
Key Events · M&A and Partnerships · NXTC
-
Reverse Merger Terms Finalized
NextCure will merge with Avere Therapeutics in a reverse merger, with legacy NextCure stockholders owning approximately 1.17% of the combined company on a fully diluted basis, down from 100% today.
-
$820M Pre-Closing Financing
Avere has secured $820 million in pre-closing financing commitments ($320M initial + $500M additional at a higher valuation), with approximately $266M to be paid via contribution and cancellation of convertible notes.
-
Exchange Ratio and Valuation
The estimated exchange ratio is 5.8265 NextCure shares per Avere share, based on a $250M Avere equity value and an $11M NextCure valuation, subject to adjustment for NextCure's net cash.
-
Reverse Stock Split and Re-Domiciliation
Stockholders will vote on a reverse stock split at a ratio to be determined, and a re-domiciliation from Delaware to Texas, both required to complete the merger.
Analysis · NXTC · Life Sciences
The S-4 registration statement provides the definitive terms of the reverse merger with Avere Therapeutics, first announced on July 14, 2026. Legacy NextCure stockholders will be diluted to approximately 1.17% ownership of the combined company, while Avere securityholders and pre-closing financing investors will own the remaining ~98.83%. The filing confirms an $820 million aggregate pre-closing financing ($320M initial + $500M additional at a higher valuation), a proposed reverse stock split, and a re-domiciliation to Texas. The deal is a lifeline for NextCure, which faces going concern risk and would likely liquidate without the merger, but it represents a near-total wipeout of existing equity value.
At the time of this filing, NXTC was trading at $6.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.